Novo Nordisk CEO on EU pharma reform: "A lose, lose, lose"
Lars Fruergaard Jørgensen, CEO of Danish drugmaker Novo Nordisk, sharply criticizes a proposed overhaul to the EU’s pharma regulation, which he says would make companies turn to the US.
by christian bundgaard, translated by daniel pedersen
The European Commission is about to release a proposal for a revision of the EU’s pharmaceuticals regulation, affecting all 27 member countries.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to expand R&D presence in Boston
For subscribers
AI Act could force innovation to flee Europe
For subscribers
.jpg&w=384&q=75)
